P.1.75: REVALUATION OF RISK FACTORS FOR INFLAMMATORY BOWEL DISEASES ACCORDING TO THE “HYGIENE HYPOTHESIS”: A SOUTH-ITALIAN, CASE-CONTROL, MULTI-CENTRE PROSPECTIVE STUDY

2011 ◽  
Vol 43 ◽  
pp. S173
Author(s):  
F. Castiglione ◽  
C. Meucci ◽  
F. Morace ◽  
M. Diaferia ◽  
A. Panarese ◽  
...  
Keyword(s):  
Risk Factors ◽  
Prospective Study ◽  
Inflammatory Bowel Diseases ◽  
Hygiene Hypothesis ◽  
Case Control ◽  
Italian Case ◽  
Bowel Diseases ◽  
Inflammatory Bowel

Environmental risk factors in inflammatory bowel diseases. Investigating the hygiene hypothesis: A Spanish case–control study

2010 ◽  
Vol 45 (12) ◽  
pp. 1464-1471 ◽  
Author(s):  
Pilar López-Serrano ◽  
José L. Pérez-Calle ◽  
Maria Teresa Pérez-Fernández ◽  
Juan Manuel Fernández-Font ◽  
Daniel Boixeda de Miguel ◽  
...  
Keyword(s):  
Risk Factors ◽  
Environmental Risk ◽  
Inflammatory Bowel Diseases ◽  
Case Control Study ◽  
Hygiene Hypothesis ◽  
Case Control ◽  
Environmental Risk Factors ◽  
Bowel Diseases ◽  
Inflammatory Bowel ◽  
Control Study

Sa574 RISK FACTORS FOR DISORDERED EATING AMONG PATIENTS WITH INFLAMMATORY BOWEL DISEASES

2021 ◽  
Vol 160 (6) ◽  
pp. S-557-S-558
Author(s):  
Gianna Stoleru ◽  
Andrew R. Leopold ◽  
Amanda Auerbach ◽  
Shelley Nehman ◽  
Uni Wong
Keyword(s):  
Risk Factors ◽  
Disordered Eating ◽  
Inflammatory Bowel Diseases ◽  
Bowel Diseases ◽  
Inflammatory Bowel

scholarly journals 1119 Genetic Risk Factors for Serious Infections in Inflammatory Bowel Diseases

2016 ◽  
Vol 150 (4) ◽  
pp. S224-S225
Author(s):  
Saranya Sasidharan ◽  
Vijay Yajnik ◽  
Hamed Khalili ◽  
John Garber ◽  
Comas Giallourakis ◽  
...  
Keyword(s):  
Risk Factors ◽  
Inflammatory Bowel Diseases ◽  
Genetic Risk ◽  
Genetic Risk Factors ◽  
Serious Infections ◽  
Bowel Diseases ◽  
Inflammatory Bowel

scholarly journals Articular manifestations in patients with inflammatory bowel disease treated with vedolizumab

Rheumatology ◽  
2020 ◽  
Vol 59 (11) ◽  
pp. 3275-3283 ◽  
Author(s):  
Anastasia Dupré ◽  
Michael Collins ◽  
Gaétane Nocturne ◽  
Franck Carbonnel ◽  
Xavier Mariette ◽  
...  
Keyword(s):  
Risk Factors ◽  
Ulcerative Colitis ◽  
Inflammatory Bowel Disease ◽  
Inflammatory Bowel Diseases ◽  
Bowel Disease ◽  
Bowel Diseases ◽  
History Of ◽  
Musculoskeletal Manifestations ◽  
Inflammatory Bowel

Abstract Objective Vedolizumab (VDZ) has been incriminated in the occurrence of articular manifestations in patients with inflammatory bowel diseases (IBDs). The aim of this study was to describe musculoskeletal manifestations occurring in IBD patients treated by VDZ and to identify risk factors. Methods In this retrospective monocentric study, we included all consecutive patients treated by VDZ for IBD in our hospital. Incident musculoskeletal manifestations occurring during VDZ treatment were analysed and characteristics of patients with and without articular inflammatory manifestations were compared. Results Between 2013 and 2017, 112 patients were treated with VDZ for IBD: ulcerative colitis (n = 59), Crohn’s disease (n = 49) and undetermined colitis (n = 4). Four patients (3.6%) had a history of SpA, whereas 13 (11.6%) had a history of peripheral arthralgia. Some 102 (91.1%) patients had previously received anti-TNF. After a mean (S.d.) follow-up of 11.4 (8.6) months, 32 (28.6%) patients presented 35 musculoskeletal manifestations, of which 18 were mechanical and 17 inflammatory. Among the latter, 11 had axial or peripheral SpA, 5 had early reversible arthralgia and 1 had chondrocalcinosis (n = 1). Among the 11 SpA patients, only 3 (2.6%) had inactive IBD and may be considered as paradoxical SpA. The only factor associated with occurrence of inflammatory manifestations was history of inflammatory articular manifestation [7/16 (43.8%) vs 10/80 (12.5%), P = 0.007]. Conclusion Musculoskeletal manifestations occurred in almost 30% of IBD patients treated with VDZ, but only half of them were inflammatory. Since most of the patients previously received anti-TNF, occurrence of inflammatory articular manifestations might rather be linked to anti-TNF discontinuation than to VDZ itself.

Sign in / Sign up

Export Citation Format

Share Document